Courtagen Life Sciences Blog

Courtagen Staff

Courtagen is a privately-held life sciences and molecular information company that converts genomic data into actionable clinical information for the diagnosis of critical pediatric neurological and metabolic disorders. Specifically, Courtagen focuses on mitochondrial disorders, epilepsy, and intellectual disability, including autism spectrum disorders.
Find me on:

Recent Posts

15 New Panels Address Ciliopathy, Endocrinology, Neuromuscular, Bone Density, and Connective Tissue

Posted by Courtagen Staff on May 15, 2017 3:31:37 PM

Our test menu has expanded, again! This month, we have added 11 new Spotlight™ panels, three new Focus™ panels, and one new Comprehensive panel, across multiple disorder types. 

Read More

Topics: Genetic Testing, Company News, endocrinology, Multi-System

11 New Spotlight™ Panels added to test menu

Posted by Courtagen Staff on Apr 6, 2017 10:15:00 AM

This month, we are happy to announce we have added another 11 tests to our growing catalog of Courtagen Spotlight™ Panels. These small (3 to 50 genes) panels provide clinicians with a targeted approach to genetic testing, and are best used when a patient's symptomatology is discernible. Each Spotlight Panel contains addresses a group of disorders with overlapping symptoms, making test selection clear and straightforward.

Read More

Topics: Genetic Testing, Company News

10 New Spotlight™ Panels for Targeted Genetic Testing

Posted by Courtagen Staff on Mar 14, 2017 10:37:00 AM

We are happy to announce the addition of 10 new tests to our Spotlight™ Panel line, which provides clinicians a targeted approach to genetic testing when a patient's symptomatology is discernible. Each Spotlight Panel contains between approximately 3 to 50 genes selected to address a group of disorders with overlapping symptoms, making test selection clear and straightforward.

Read More

Topics: Genetic Testing, Company News

Courtagen Receives Notice of Allowance for a Genetically Targeted Pain Therapy Patent

Posted by Courtagen Staff on Feb 24, 2017 11:45:04 AM

We are excited to announce that we received a Notice of Allowance from the United States Patent and Trademark Office for a patent that uses a personalized medicine approach to match genetic markers for chronic pain with therapeutic drugs, including the cannabis-derived compound cannabidiol.

Read More

Topics: Genetic Testing, Cannabis, Chronic Pain

New Spotlight Panels are Here!

Posted by Courtagen Staff on Feb 7, 2017 12:20:24 PM

We are happy to announce that we have added 17 new gene panels to our Spotlight line of tests. These new tests will expand our menu by 65%, offering new testing options in neurology, endocrinology, epilepsy, developmental delay, mitochondrial disease, and other disease areas.

Read More

Topics: Epilepsy, Genetic Testing, Genetics, endocrinology

Genetic Testing Helps Patient Beat 10 Year Battle with Seizures

Posted by Courtagen Staff on Jan 13, 2017 2:42:20 PM

 

Read More

Topics: Epilepsy, Genetic Testing, Success Story

Is Cannabis a Reasonable Option for Treating Epilepsy?

Posted by Courtagen Staff on Nov 10, 2016 2:06:00 PM

Earlier this week, voters in four states (Arkansas, Florida, Montana, and North Dakota) approved legislation that made medicinal marijuana legal in their respective states. Now more than half the states have approved medical marijuana in some form. It’s fitting that this landmark was reached in the month of November, which happens to be Epilepsy Awareness month.

Read More

Topics: Epilepsy, Genetics, Cannabis

We Have a New Home

Posted by Courtagen Staff on Oct 14, 2016 11:37:07 AM

Last week we packed up our computers, sequencers, pipettes, and numerous test tubes filled with saliva to move down the road to our new headquarters at 8 Cabot Road Woburn, MA.

Read More

Topics: Company News

Courtagen Partners with UMDF to Provide Complementary Genetic Testing for Mitochondrial disorders

Posted by Courtagen Staff on Sep 8, 2016 12:30:00 PM

Courtagen is excited to announce that it has partnered with the United Mitochondrial Disease Foundation as part of a new pilot program designed to expand access to genetic testing for patients with mitochondrial disorders who have been unable to access testing due to financial barriers.

Read More

Topics: Courtagen Gives Back

Upcoming Webinar: The Role of Genetic Testing Panels in Clinical Practice

Posted by Courtagen Staff on Jul 27, 2016 4:08:36 PM
Genetic testing has become a powerful addition to the clinician's toolbox that can be deployed to help identify a definitive diagnosis and inform patient care, especially for neurological and metabolic disorders. 
 
Read More

Topics: Epilepsy, Mitochondrial Disorders, Genetic Testing, Genetics, Developmental Delay